By a News Reporter-Staff News Editor at Biotech Week Aethlon Medical, Inc., released the following note authored by its Chairman and CEO, Jim Joyce. In this regard, FDA withheld clearance of our recently amended IDE based on a single information deficiency that was deemed a safety concern. Specifically, FDA has requested that we detail our traini
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on May 7, 2013. The SEC file number is 0001100412-13-000007.. A U.S. Securities and Exchange Commission filing is a formal do
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on May 7, 2013. The SEC file number is 0001104659-13-038316.. A U.S. Securities and Exchange Commission filing is a formal do
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Array Biopharma Inc. was posted on May 6, 2013. The SEC file number is 0001144204-13-026478.. A U.S. Securities and Exchange Commission filing is a formal do
ENP Newswire- 22 May 2013. Release date- 21052013- ALISO VIEJO, CA.- Bausch+ Lomb, the global eye health company, today announced that it is has received approval from the U.S. Food and Drug Administration for the TRULIGN Toric posterior chamber intraocular lens. Jay Pepose, M.D., Ph.D, of the Pepose Vision Institute in St. Louis, MO, and medical m
By a News Reporter-Staff News Editor at Biotech Week The Biotechnology Industry Organization and the ViS Research Institute announce a new initiative aimed at improving the efficiency of clinical development for pediatric therapeutics. The U.S. FDA and European Medicines Agency require pediatric study plans before approval of new therapeutics.
By a News Reporter-Staff News Editor at Biotech Week BioLineRx Ltd., a biopharmaceutical development company, announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present at the Oppenheimer 14th Annual Israeli Conference on Sunday, May 12, 2013, at 12:00 p.m. Isra
By a News Reporter-Staff News Editor at Biotech Week Bristol-Myers Squibb Company will present at Bank of America Merrill Lynch Health Care Conference on Wednesday, May 15, 2013, in Las Vegas. Giovanni Caforio, president, U.S. Pharmaceuticals, will make a formal presentation about the company at 10 a.m. PDT. Keywords for this news article include
Release date- 17052013- Ingelheim Germany,- Professor Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim GmbH, with responsibility for Biopharmaceuticals and Production, has decided to step down from the Board of Managing Directors of Boehringer Ingelheim GmbH effective 30 June 2013 and to leave the corporation.
By a News Reporter-Staff News Editor at Biotech Week Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000 s, while the number of new cancer drugs entering clinical testing increased 50 percent during the same time, according to an analysis recently completed by the Tufts Center for the Study of Drug Developm
By a News Reporter-Staff News Editor at Biotech Week Connie Wierman, a seasoned executive with more than 25 years of biopharmaceutical experience, has been named vice president of biopharmaceutical development for Theorem Clinical Research. Wierman held a number of executive posts at leading industry firms prior to joining Theorem, including vice
By a News Reporter-Staff News Editor at Biotech Week Cubist Pharmaceuticals, Inc. announced that Robert Perez, Cubist's President and COO, will present at the Bank of America Merrill Lynch 2013 Healthcare Conference on Wednesday, May 15, to discuss the company's business activities, financial outlook, and current news. The conference will be held
For the fifth consecutive year, Cubist Pharmaceuticals, Inc. has been named to the Globe 100 annual list, the Boston Globe's annual ranking of the 100 top-performing public companies headquartered in Massachusetts. The 2013 list was published in the Globe 100 Magazine in the Sunday Boston Globe on May 19. Based on a composite score derived from fin
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Galena Biopharma, Inc. was posted on May 2, 2013. The SEC file number is 0001250853-13-000072.. A U.S. Securities and Exchange Commission filing is a formal
By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Galena Biopharma, Inc. was posted on May 2, 2013. The SEC file number is 0001193125-13-195444.. A U.S. Securities and Exchange Commission filing is a formal
By a News Reporter-Staff News Editor at Biotech Week GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces that it has received commercialization approval for its prescription medicine Sativex in Italy.
Impax Laboratories, Inc. announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the U.S., as part of a Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited. According to IMS Health data, U.S. sales of Z
NanoPass Technologies, a company focusing on intradermal vaccine delivery solutions, said that it is collaborating with the US Center of Disease Control and prevention in conducting a large phase 3 trial of polio vaccine in infants in South East Asia. In a release, the Company noted:. This collaboration is a part of NanoPass's long-term commitment
By a News Reporter-Staff News Editor at Biotech Week Nimbus Discovery, LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, announced a co-development agreement with Shire plc focused on small molecule treatments for several rare genetic diseases known as lysosomal storage disorder
Orexigen Therapeutics, Inc. announced that management will present a company overview at the UBS Global Healthcare Conference in New York. According to a release, the presentation is scheduled for Wednesday, May 22 at 11 a.m. Eastern Time. Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity.
Dublin- Research and Markets has announced the addition of the "Preventative Medicine Partnering 2007-2013" report to their offering. Preventative Medicine Partnering 2007-2013 report provides understanding and access to the preventative medicine partnering deals and agreements entered into by the worlds leading healthcare companies.
Puma Biotechnology, Inc., a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding the trading in the Company's common stock. In a release, the Company noted that it is the Company's policy not to comment on trading activity. Puma Biotechnology, Inc. is a development stage biopharmaceutical company
Puma Biotechnology, Inc., a development stage biopharmaceutical company, has been contacted by the New York Stock Exchange regarding the trading in the Company's common stock. According to a release, it is the Company's policy not to comment on trading activity. Puma Biotechnology, Inc. is a development stage biopharmaceutical company.
By a News Reporter-Staff News Editor at Biotech Week Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 4:20 p.m. PDT on Wednesday, May 15, at the Bank of America Merrill Lynch 2013 He
Peter J. Shaw to the position of Chief Medical Officer. He previously served as President and Chief Operating Officer of MD Mindset, LLC, a pharma sales force and marketing effectiveness firm, with day-to- day responsibility for company operations, product development, and business development. Prior to this, he was the President and founder of Lon
